USP47 Inhibitors Induce Apoptosis via Deubiquitination Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective cancer treatments that regulate or affect the cell cycle to stimulate apoptosis in cancer cells, particularly for targeting USP47, a cysteine protease and deubiquitinating enzyme involved in cell cycle regulation, with a need for small molecule inhibitors as cancer chemotherapeutics.
Innovation Solution
Development of methods and kits to screen for and utilize USP47 inhibitors, including siRNA, to induce apoptosis in target cells by contacting them with effective amounts of USP47 inhibitors, potentially combined with DNA damage-sensitizing agents, and employing kits for screening USP47 and β-TrCP protein interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatment methods are used, then general cancer therapy is provided, but effective regulation of cell cycle to stimulate apoptosis in cancer cells is not achieved
Solution Approach 1:
The patent uses USP47 as an intermediary target in the ubiquitin pathway to indirectly regulate cell cycle progression and induce apoptosis. By inhibiting USP47, the patent affects downstream targets such as β-TrCP and other substrates, creating a cascade effect that leads to cell death while maintaining specificity for cancer cells with dysregulated ubiquitin pathways.
Solution Approach 2:
The patent changes the parameter of protease activity by introducing USP47 inhibitors that block the deubiquitination function of USP47. This parameter change leads to accumulation of ubiquitinated substrates, altered protein degradation rates, and ultimately cell cycle arrest and apoptosis in cancer cells.
2Reliability
If small molecule inhibitors are developed to target USP47, then specific cancer chemotherapy is achieved, but the complexity of identifying and screening effective inhibitors increases
Solution Approach 1:
The patent employs cell-based assays where cancer cells themselves serve as the screening system. The cells express USP47 and its substrates, allowing inhibitors to be screened in their native cellular context. This self-service approach eliminates the need for complex in vitro reconstitution systems while maintaining physiological relevance.
Solution Approach 2:
The patent develops a universal screening platform that can identify inhibitors of USP47 activity applicable to multiple cancer types. The assay system is designed to detect USP47 inhibition across different cell lines and cancer models, making the screening process broadly applicable rather than disease-specific.
3Reliability
If USP47 is inhibited to induce apoptosis, then cancer cell death is achieved, but the mechanism of action requires understanding of complex ubiquitin pathway interactions
Solution Approach 1:
The patent employs fluorescent or colorimetric reporters that change signal intensity or wavelength in response to USP47 activity. For example, fluorogenic substrates release fluorescent signals upon deubiquitination by active USP47, allowing real-time measurement of enzyme activity and inhibition without complex instrumentation.
Solution Approach 2:
The patent uses simplified reporter systems that copy the essential function of USP47 substrates but with measurable outputs. Instead of measuring actual protein degradation rates directly, the patent uses reporter proteins or peptides that mimic substrate properties and provide quantifiable signals proportional to USP47 activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively induces apoptosis in cancer cells by inhibiting USP47, potentially leading to cell death and providing a method for cancer treatment by increasing the degradation rate or decreasing the amount of USP47, thereby regulating cell cycle and inducing apoptosis.
Implementation Method 1
USP47, a cysteine protease and deubiquitinating enzyme involved in cell cycle regulation
Implementation Method 2
including siRNA
Implementation Method 3
The ubiquitin/proteasome system is responsible for most protein turnover in the mammalian cell
Implementation Method 4
The ubiquitin pathway leads to the covalent attachment of a poly-ubiquitin chain to target substrates
Data Source
AI summary
The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.